Best AI radiology and imaging, in 2026
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.
- 33
- 33
- May 23, 2026
Which radiology are worth shortlisting in 2026?
Four tools survived our 2026 review for clinical use: Aidoc for acute-care triage; Viz.ai for stroke + cardio coordination; DeepHealth for global radiology ai portfolio; HeartFlow for reimbursable ccta ai.
Four tools we actually recommend
Each pick wins a specific use case. The wrong question is “which is best”. The right question is “which fits my situation”. Skip past the ones not matching yours.
by Aidoc
Most-deployed acute-care triage AI in US hospitals (1,000+ sites).
31+ FDA clearances across stroke, PE, ICH, C-spine. Foundation model CARE1 across modalities.
- Enterprise (~$50k+/site/yr baseline, module-based).
- FDA 510(k) (multiple) / CE-IVDR / HIPAA
by Viz.ai
Stroke + cardio + PE coordination at 1,700+ US hospitals.
50+ FDA clearances. Strongest care-coordination workflow layer beyond pure detection.
- Enterprise (per-site subscription).
- FDA 510(k) (multiple) / HIPAA
by RadNet
World's largest after Gleamer acquisition (March 2026).
RadNet-owned. CXR, mammography, CT, MRI. ~$140M ARR projected EOY 2026. Spans CV + onc + neuro.
- Enterprise per-site / per-study.
- —
by HeartFlow
Non-invasive CCTA-derived FFR, reimbursable since CPT 75577 (Jan 2026).
Most clinical-evidence-backed CCTA AI. IPO filed 2026. Eliminates invasive angiography for many patients.
- Enterprise (per-study, reimbursable).
- FDA De Novo / CE-IVDR
What should clinicians look for when buying radiology?
The right tool depends on your workflow, your specialty, your budget, and your scale. Five criteria do most of the work narrowing your shortlist.
FDA clearance and clinical evidence
510(k) or De Novo clearance is the floor. Beyond that, look at peer-reviewed prospective evidence — most published AI radiology evidence is retrospective.
Workflow embed
PACS integration depth matters more than algorithm accuracy in 80% of cases. Aidoc + Viz.ai win on workflow; smaller vendors often fail at integration scale.
Modality and pathology coverage
Single-condition vendors (HeartFlow for FFR, Viz.ai for stroke) deliver best-in-class on their target. Suite vendors (Aidoc, DeepHealth) trade peak performance for coverage breadth.
Reimbursement and ROI
HeartFlow has CPT 75577 ($1,000+ per study). Cleerly has limited reimbursement. Aidoc and Viz.ai bill on subscription. Reimbursable workflows have clearer ROI math.
Foundation model trajectory
Aidoc CARE1 and similar foundation models are eating modular AI. If you're buying for 5 years, vendor foundation-model investment matters more than current FDA count.
How do all 33 platforms compare side-by-side?
Pricing from vendor documentation, certifications verified against public attestations. Highlighted rows were directly evaluated by an MD on our editorial team within the past six months.
| Ref | Tool | From | Founded | Compliance / EHR | Action |
|---|---|---|---|---|---|
| RD-001 |  | Enterprise (~$50k+/site/yr baseline, module-based). | 2016 | FDA 510(k) (multiple)CE-IVDRHIPAA | Visit |
| RD-002 | Enterprise (per-study). | — | Visit | ||
| RD-003 |  | Enterprise. | — | Visit | |
| RD-004 |  | Enterprise. | — | Visit | |
| RD-005 |  | Enterprise. | — | Visit | |
| RD-006 |  | Enterprise + OEM. | — | Visit | |
| RD-007 | Enterprise. | — | Visit | ||
| RD-008 |  | Enterprise (per-study). | — | Visit | |
| RD-009 | Enterprise. | — | Visit | ||
| RD-010 |  | Enterprise per-site / per-study. | — | Visit | |
| RD-011 |  | Enterprise. | — | FDA 510(k) | Visit |
| RD-012 |  | Enterprise. | — | Visit | |
| RD-013 |  | Enterprise + OEM-bundled. | — | FDA 510(k) (multiple)CE-IVDRHIPAA | Visit |
| RD-014 |  | Enterprise (per-study, reimbursable). | — | FDA De NovoCE-IVDR | Visit |
| RD-015 |  | OEM-bundled with Hologic 3D Mammography. | — | Visit | |
| RD-016 |  | Capital equipment + service. | — | Visit | |
| RD-017 |  | Enterprise. | — | Visit | |
| RD-018 |  | Enterprise + OEM-embedded. | — | Visit | |
| RD-019 | Enterprise. | — | Visit | ||
| RD-020 |  | Enterprise + OEM. | — | Visit | |
| RD-021 | Enterprise (per-study, often grant-funded). | — | Visit | ||
| RD-022 |  | Enterprise. | — | Visit | |
| RD-023 |  | Enterprise. | 2017 | Visit | |
| RD-024 |  | Enterprise. | — | Visit | |
| RD-025 |  | Enterprise. | — | Visit | |
| RD-026 |  | Enterprise. | — | Visit | |
| RD-027 |  | Enterprise + OEM. | — | FDA 510(k) (multiple)CE-IVDR | Visit |
| RD-028 |  | Enterprise. | — | Visit | |
| RD-029 |  | Enterprise. | — | Visit | |
| RD-030 |  | Enterprise. | — | Visit | |
| RD-031 |  | Enterprise + OEM. | — | Visit | |
| RD-032 |  | Enterprise. | — | Visit | |
| RD-033 |  | Enterprise (per-site subscription). | 2016 | FDA 510(k) (multiple)HIPAA | Visit |
Scroll horizontally to see all columns.
Where radiology touch the rest of the stack
What do clinicians ask about radiology?
Sourced from radiology administrators, imaging informaticists, and KLAS research summaries.
Browse all questionsDeeper articles
Best AI Study Tools for USMLE Step 1 in 2026
Step 1 has been pass/fail since 2022, but the content load hasn't shrunk. We compare UWorld, AMBOSS, Anki/AnKing, SketchyMedical, and Pathoma for medical students preparing in 2026.
Read article
AI for Prior Authorization in 2026: Cohere, Waystar, and the State of Automation
Prior authorization remains the most expensive friction in US revenue cycle. We map the AI vendors closing that gap in 2026: Cohere Health on the payer side, Waystar on provider RCM, and the realistic state of automation.
Read article
Heidi Health vs Freed AI: Head-to-Head for Solo Clinicians (2026)
Both cost around $99 a month, both are HIPAA compliant, both work in a browser. We compared Heidi Health and Freed AI on note quality, template flexibility, language support, and onboarding for solo practice.
Read article